List of Excipients in Branded Drug AMBRISENTAN

« Back to Dashboard

Generic Drugs Containing AMBRISENTAN

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	ambrisentan	0378-4270	ANHYDROUS LACTOSE
Mylan Pharmaceuticals Inc	ambrisentan	0378-4270	CELLULOSE, MICROCRYSTALLINE
Mylan Pharmaceuticals Inc	ambrisentan	0378-4270	CROSCARMELLOSE SODIUM
Mylan Pharmaceuticals Inc	ambrisentan	0378-4270	FD&C BLUE NO. 2
Mylan Pharmaceuticals Inc	ambrisentan	0378-4270	FD&C RED NO. 40

What are the Most Frequently-Used Excipients in AMBRISENTAN?

# Of NDCs	Excipient
7	ALUMINUM OXIDE
2	ANHYDROUS LACTOSE
16	CELLULOSE, MICROCRYSTALLINE
16	CROSCARMELLOSE SODIUM
3	FD&C BLUE NO. 2

Ambrisentan Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Ambrisentan is an oral endothelin receptor antagonist for pulmonary arterial hypertension, marketed originally as Letairis by Gilead Sciences. The principal commercial opportunity is generic and differentiated formulation development rather than a new chemical entity. A viable product must control dissolution, content uniformity, tablet robustness, stability, and bioequivalence across the 5 mg and 10 mg strengths. Because ambrisentan is a small molecule, biosimilar regulation does not apply. Generic products proceed through the abbreviated new drug application, or ANDA, pathway.

The strongest opportunities are low-cost immediate-release tablets, supply-secure formulations that remove vulnerable excipients, and specialty products designed for global markets where formulation simplicity and manufacturing reliability matter more than novel delivery technology.

What is ambrisentan and how is it regulated?

Ambrisentan is a selective endothelin type A receptor antagonist. The FDA approved Letairis in 2007 for pulmonary arterial hypertension, including patients in WHO functional class II or III, to improve exercise capacity and reduce clinical worsening risk.[1]

Attribute	Data
Active ingredient	Ambrisentan
Drug class	Endothelin receptor antagonist
Primary indication	Pulmonary arterial hypertension
Original brand	Letairis
Innovator	Gilead Sciences
FDA dosage forms	Immediate-release tablets
Strengths	5 mg and 10 mg
Generic pathway	ANDA
Biologic status	Not a biologic; biosimilar pathway does not apply
Core commercial issue	Generic competition and formulation execution

Letairis is administered orally once daily. The commercial product is a film-coated tablet. The label identifies conventional tablet excipients, including lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, povidone and coating components.[1,2]

The product has a relatively low dose, which reduces the active-ingredient loading challenge. The formulation still requires tight control of blend uniformity because a 5 mg tablet contains a small quantity of active pharmaceutical ingredient.

What excipient strategy is appropriate for ambrisentan tablets?

A conventional immediate-release matrix is the most defensible starting point. The formulation should prioritize rapid and reproducible drug release, low tablet weight, adequate mechanical strength and low sensitivity to lubricant overmixing.

Recommended excipient functions

Formulation function	Candidate excipient classes	Commercial rationale
Diluent	Lactose monohydrate, microcrystalline cellulose, mannitol, dibasic calcium phosphate	Controls tablet weight, flow and compactability
Binder	Povidone, copovidone, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Supports immediate drug release
Glidant	Colloidal silicon dioxide	Improves powder flow and die filling
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces sticking and ejection force
Film former	Hypromellose or polyvinyl alcohol	Protects the tablet and supports identification
Opacifier and colorant	Titanium dioxide and permitted pigments	Provides strength differentiation and light protection where needed

The commercial formulation objective is not maximum excipient innovation. It is a robust design that reproduces the reference product’s dissolution profile without relying on a narrow manufacturing window.

Lactose-based versus lactose-free designs

A lactose-based formulation can closely track the established product and usually offers favorable cost and processing characteristics. A lactose-free platform can create a differentiated product for patients with lactose intolerance, procurement systems that prefer allergen-minimized products, or markets where lactose supply is exposed to regional shortages.

Microcrystalline cellulose and mannitol can replace lactose, but the substitution changes bulk density, compactability, water activity and disintegration. A lactose-free formulation therefore requires a full bioequivalence and dissolution assessment rather than a simple excipient swap.

Direct compression versus wet granulation

Direct compression is attractive because it reduces processing steps, solvent exposure and manufacturing cost. It requires excipients with consistent flow and compaction properties. Low-dose ambrisentan can create segregation risk if the active ingredient has a particle-size distribution that differs materially from the diluent.

Wet granulation can improve content uniformity and reduce segregation. It may be preferable where the API has poor flow, poor compactability or electrostatic behavior. The tradeoff is higher cost, more process variables and potential moisture exposure.

A practical development sequence is:

1. Screen direct compression with microcrystalline cellulose, lactose or mannitol.
2. Measure blend uniformity at commercial-scale mixing conditions.
3. Evaluate roller compaction if direct compression produces segregation.
4. Use aqueous or nonaqueous wet granulation only if powder engineering does not resolve the issue.
5. Optimize lubricant concentration and mixing time because over-lubrication can slow dissolution.

What physicochemical properties drive ambrisentan formulation development?

Ambrisentan is generally treated as a low-solubility small molecule, making dissolution a central quality attribute. Formulation work should evaluate pH-dependent solubility, particle size, polymorphic form, wetting, powder flow and tablet disintegration.

The key risk is a formulation that passes tablet hardness and assay testing but produces a slower or more variable dissolution profile than the reference product. A robust development program should include:

• API particle-size distribution and surface-area characterization.
• Solid-state and polymorph assessment.
• Compatibility testing with lactose, cellulose, povidone, superdisintegrants and lubricants.
• Dissolution profiling across multiple pH conditions.
• Sensitivity studies for compression force, lubricant level and disintegration-agent concentration.
• Stability testing under long-term and accelerated conditions.
• Extractables and leachables assessment for packaging systems.
• Moisture uptake and water-activity studies.

A surfactant or lipid-based system may improve wetting, but it adds manufacturing and regulatory complexity. Such systems are more commercially defensible when conventional excipients cannot provide reliable dissolution or when a new dosage form targets a defined patient segment.

What formulations are protected by ambrisentan patents?

The main historic intellectual-property protection centered on the ambrisentan chemical entity and related endothelin receptor antagonist chemistry. U.S. Patent No. 6,410,550 is one of the principal patents associated with ambrisentan-related compound protection.[3]

Patent protection should be separated into four categories:

Protection category	Relevance to ambrisentan
Compound patents	Historically important for the active molecule and core commercial launch
Formulation patents	May cover tablet composition, release characteristics or excipient combinations
Method-of-use patents	May cover treatment of pulmonary arterial hypertension or specific patient populations
Process patents	May cover API synthesis, purification, crystallization or particle engineering

For a generic tablet, the compound patent position is less important after expiration than any later-expiring method-of-use, formulation or manufacturing patent listed in the FDA Orange Book. An ANDA applicant must conduct a current patent certification review under Paragraph I, II, III or IV. The Orange Book remains the operative source for listed patents and exclusivity information.[4]

Are Paragraph IV challenges relevant to ambrisentan?

Yes. An ANDA applicant may use a Paragraph IV certification to state that an Orange Book-listed patent is invalid, unenforceable or will not be infringed. The filing can trigger patent litigation under the Hatch-Waxman framework and may create a 30-month stay of approval, subject to statutory conditions.[5]

Ambrisentan applicants should assess:

• Whether listed patents cover the proposed tablet composition.
• Whether the proposed label overlaps patented methods of use.
• Whether a section viii statement can carve out a patented indication or patient population.
• Whether the reference product’s dosage strengths and labeling create design-around constraints.
• Whether litigation settlements include launch dates, licenses, supply terms or restrictions.

The presence of an Orange Book-listed patent does not itself establish a blocking patent. The scope of the claims, the proposed label and the applicant’s formulation must be analyzed together.

When does ambrisentan lose exclusivity?

Ambrisentan’s original orphan-drug exclusivity period has expired. FDA orphan-drug exclusivity generally lasts seven years from approval and prevents approval of the same drug for the same indication, subject to statutory exceptions.[6]

The original compound patent estate also reached the end of its principal term around 2020, depending on patent-term adjustment, patent-term extension and pediatric exclusivity. Current market access depends on the specific Orange Book entries, later patents and ANDA litigation outcomes rather than the original 2007 approval date.

Exclusivity type	Ambrisentan position
Orphan-drug exclusivity	Expired
New chemical entity exclusivity	Expired
Pediatric exclusivity	Must be checked against the historical patent record
Compound patent protection	Principal historic term ended around 2020, subject to adjustment
Formulation or method patents	Must be reviewed in the current Orange Book
Generic approval pathway	ANDA
Biosimilar pathway	Not applicable

What is the Orange Book status of ambrisentan?

The Orange Book identifies approved products, therapeutic equivalence information, listed patents and exclusivity data. The record must be reviewed by strength and applicant because listed patents and marketing status can change over time.[4]

For commercial planning, the relevant questions are:

1. Does the reference product remain actively marketed?
2. Which generic ambrisentan tablets have final approval?
3. Are any products tentatively approved because of patent or exclusivity barriers?
4. Do approved generics have both 5 mg and 10 mg strengths?
5. Are there any product-specific labeling restrictions?
6. Are current patents directed to use, formulation or manufacture?

Ambrisentan is a small-molecule product, so an approved generic that demonstrates pharmaceutical equivalence and bioequivalence can receive an AB therapeutic-equivalence rating where the FDA’s criteria are satisfied. The rating supports pharmacy substitution under applicable state law and payer policy.

How strong is the ambrisentan patent estate?

The patent estate is weaker for a conventional generic tablet than for a new formulation or manufacturing platform. The historic compound protection has largely run its course, and the product does not have the biologic complexity that creates biosimilar barriers.

The remaining risks are narrower:

• Later-expiring formulation claims.
• Method-of-use patents affecting the proposed label.
• API process patents that raise supply or freedom-to-operate concerns.
• Patent settlements that delay launch.
• Regulatory exclusivity associated with a later-approved product or indication.
• Trade secrets controlling a low-cost or high-purity API route.

A formulation using the same broad excipient classes as the reference product is commercially practical, but it should not copy any claim-specific ratios, processing steps or release characteristics without a claim chart and freedom-to-operate analysis.

What manufacturing and IP barriers affect ambrisentan?

API supply is likely to be more important than tablet technology. A generic manufacturer needs at least one qualified source with consistent impurity control, particle-size control and solid-state properties.

Manufacturing risks

• Low-dose blend uniformity.
• API segregation during transport and hopper feeding.
• Variation in particle size across API lots.
• Slow dissolution after lubricant overmixing.
• Tablet sticking during compression.
• Moisture-driven stability changes.
• Color or coating variability across strengths.
• Dependence on a single API supplier.

IP risks

The applicant should review patents covering:

• Ambrisentan synthesis and intermediates.
• Crystalline or amorphous forms.
• Particle-size or micronization processes.
• Salt or solvate forms.
• Tablet compositions.
• Modified-release systems.
• Pulmonary hypertension treatment methods.
• Combination use with tadalafil or other pulmonary arterial hypertension therapies.

An excipient strategy that uses well-established ingredients and avoids unusual ratios can reduce both technical and patent risk. A formulation patent may create value only if it delivers a meaningful manufacturing or clinical advantage that competitors cannot easily reproduce.

What commercial opportunities exist for ambrisentan?

Generic immediate-release tablets

The largest opportunity is a reliable 5 mg and 10 mg generic tablet. A supplier that offers both strengths, stable inventory and consistent wholesaler service can compete even in a price-eroded market.

Lactose-free or low-allergen tablets

This is a modest but potentially defensible niche. The product would need to maintain equivalent dissolution, tablet performance and stability while using alternative diluents and binders.

Global-market formulations

A formulation designed for multiple jurisdictions can reduce registration and supply complexity. The main requirements are excipients accepted across target markets, scalable manufacturing and packaging that supports diverse labeling requirements.

Hospital and specialty-pharmacy supply

Pulmonary arterial hypertension is managed through specialty channels. Buyers may value continuity of supply, predictable lead times and dual-strength availability. A manufacturer with a stable supply record can gain share without introducing a novel dosage form.

Combination-therapy packaging

Ambrisentan is used in treatment strategies that may include tadalafil. A co-pack or adherence-oriented packaging system could create commercial value, but a fixed-dose combination would require new development and regulatory review. Any combination product also requires assessment of patent and labeling rights for the companion drug.

Alternative dosage forms

Oral suspensions, orally disintegrating tablets and sprinkle formulations could address swallowing or administration needs. These products face higher development risk than standard tablets and may not justify investment unless the target population and reimbursement pathway are clear.

How does ambrisentan compare with competing pulmonary hypertension drugs?

Product	Drug class	Formulation opportunity	Generic or biosimilar risk
Ambrisentan	Endothelin A antagonist	Conventional tablet; potential lactose-free or adherence packaging	Generic risk
Bosentan	Dual endothelin receptor antagonist	Tablet and dispersible formulations	Generic risk; established competition
Macitentan	Endothelin receptor antagonist	Film-coated tablet; formulation and method patents may matter	Generic risk depends on patent estate
Tadalafil	PDE-5 inhibitor	Tablet and combination-therapy positioning	Generic risk
Selexipag	Prostacyclin receptor agonist	Tablet formulation with more complex IP considerations	Generic risk depends on remaining patents
Treprostinil	Prostacyclin analogue	Injectable, inhaled and oral delivery systems	Device and formulation barriers

Ambrisentan has a relatively straightforward tablet platform. Its commercial weakness is limited formulation differentiation. Its strength is a simpler regulatory path and lower manufacturing complexity than injectable or device-based pulmonary hypertension products.

What generic launch scenarios exist for ambrisentan?

Scenario 1: Multi-source generic erosion

Several ANDA-approved suppliers enter with 5 mg and 10 mg tablets. Prices decline rapidly, and the commercial advantage shifts to API cost, manufacturing yield and distribution reliability.

Scenario 2: Limited supplier market

A small number of manufacturers remain active because of market size, specialty distribution requirements or API constraints. Prices decline more slowly, creating value for a dependable second-source supplier.

Scenario 3: Differentiated formulation entry

A lactose-free, globally harmonized or adherence-oriented product wins a specialty segment. The product must show a concrete procurement or patient-use advantage to justify development costs.

Scenario 4: Litigation-delayed entry

A Paragraph IV certification triggers patent litigation or a settlement with a defined launch date. The applicant’s value depends on the settlement terms, first-filer status and ability to preserve commercial exclusivity.

What licensing deals and litigation affect ambrisentan?

Gilead acquired rights to ambrisentan through its acquisition of Myogen in 2006. Letairis was subsequently commercialized by Gilead.[7] The central licensing question for a generic developer is whether any active patent, settlement or supply agreement restricts manufacturing, launch timing or use of a particular API source.

A litigation review should include:

• Gilead’s historical patent litigation involving ANDA applicants.
• Patent numbers listed for the reference product.
• Complaint dates and asserted claims.
• Final judgments or settlement agreements.
• Authorized-generic arrangements.
• First-filer status and 180-day exclusivity implications.
• Any covenant not to sue or licensed launch date.

Public litigation databases and the FDA Orange Book should be reconciled before investment approval. Patent status can differ between the reference product, an authorized generic and an ANDA applicant.

Key Takeaways

• Ambrisentan is a small-molecule pulmonary arterial hypertension drug with generic, not biosimilar, competition.
• The best initial formulation is an immediate-release 5 mg and 10 mg tablet.
• Dissolution, blend uniformity, particle-size control and lubricant sensitivity are the main technical risks.
• A lactose-based formulation offers the lowest execution risk; a lactose-free product offers limited differentiation.
• Direct compression can reduce cost, but wet granulation may be needed to control segregation and content uniformity.
• The principal historic compound patent protection has expired or reached the end of its term, subject to patent-specific adjustments.
• Current Orange Book patents, method-of-use claims, formulation claims and Paragraph IV litigation must be reviewed before launch.
• Commercial value depends on API security, dual-strength availability, specialty-pharmacy supply and manufacturing yield.
• A novel delivery system is unlikely to outperform a reliable, low-cost tablet unless it solves a defined patient or procurement problem.

FAQs About Ambrisentan Excipient and Commercial Strategy

Can lactose be removed from a generic ambrisentan tablet?

Yes. Lactose can be replaced with microcrystalline cellulose, mannitol or another suitable diluent, but the revised formulation must demonstrate comparable quality, dissolution and bioequivalence.

Is ambrisentan subject to biosimilar competition?

No. Ambrisentan is a chemically synthesized small molecule. Competing products are regulated as generics through the ANDA pathway.

Which excipient is most important for ambrisentan dissolution?

The disintegrant system is usually central, but dissolution depends on the combined effects of particle size, wetting, diluent selection, compression force and magnesium stearate exposure.

Could an ambrisentan orally disintegrating tablet be commercially valuable?

Potentially, but only if it addresses a documented swallowing or adherence need. It would require new formulation, stability, taste and bioequivalence work.

What is the highest-value IP opportunity in ambrisentan manufacturing?

A defensible process that lowers API cost, improves impurity control or produces consistent particle properties may have greater value than a narrow tablet-excipient patent, provided it is difficult for competitors to design around.

References

1. U.S. Food and Drug Administration. (2024). Letairis (ambrisentan) prescribing information.
2. National Library of Medicine. (2024). DailyMed: Letairis and ambrisentan tablet labeling.
3. U.S. Patent No. 6,410,550. (2002). Pyrimidine derivatives.
4. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Food and Drug Administration. (2018). Thirty-month stays and patent certifications under the Hatch-Waxman Amendments.
6. U.S. Food and Drug Administration. (2023). Orphan drug designation and exclusivity.
7. Gilead Sciences, Inc. (2006). Annual report and acquisition disclosures regarding Myogen, Inc.